Study of the Oral Drug Tideglusib for Treating Genetic Arrhythmogenic Cardiomyopathy in Adults

What this Trial Is About

Researchers are investigating the potential benefits of tideglusib, a drug that inhibits glycogen synthase kinase-3 beta, in patients with arrhythmogenic cardiomyopathy ACM, a genetic heart disease that increases the risk of dangerous heart rhythms and sudden cardiac death. This phase 2 study focuses on patients with specific genetic variants linked to ACM and aims to better understand how tideglusib might affect the disease. The trial is randomized, double-blind, and placebo-controlled to ensure reliable results. Participants are randomly assigned to receive either tideglusib 1 gram by mouth daily or a matching placebo for six months. The study compares the effects of this treatment on heart rhythm irregularities and heart function. The treatment phase is followed by assessments to monitor changes in premature ventricular contractions and other heart-related outcomes. Throughout the study, participants will undergo evaluations including heart rhythm monitoring using Holter devices, assessments of ventricular strain, and tracking of implantable cardioverter-defibrillator ICD therapies. Researchers will measure the number of premature ventricular contractions and episodes of sustained ventricular tachycardia before and after six months of treatment. Safety and adherence will be monitored during this period, and the total participation lasts approximately six months.

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy